Transcenta Among Chinese Biotechs Raising Funds Through Public Offerings, Private Financings
Healthy Investment In-Flow Continues
A combined $447.2m are raised through a Hong Kong initial public offering (IPO) and venture capital and private equity deals.
You may also be interested in...
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Two Chinese firms join forces to develop mRNA vaccines; UK and India resolve issues over the travel of vaccinated individuals; and Scrip speaks to the CEO of a Canadian firm developing mRNA vaccines.